NLRP3 is involved in ovarian cancer chemoresistance with downregulation increasing drug sensitivity in gemcitabine‐resistant cell lines and overexpression inducing IL‐1β, EMT, and Wnt/β‐catenin signaling.215. Here, NLRP3 is linked to ovarian cancer.